Revolutionary X-ray treatment offers hope for diseased eyes

• Non-invasive Oraya therapy suppresses circulation system growth - reducing inflammation and skin damage from the eye

By Rachel Reilly

Released: 22:03 GMT, 22 December 2012

An innovative new strategy to wet age-related macular degeneration (wet AMD) has already established its global launch within the United kingdom.

Wet AMD is really a ailment that causes blindness within the center from the eye and affects 420,000 British people.

The problem evolves when abnormal bloodstream ships cluster underneath the macula – negligence the attention accountable for detailed central vision – and leak, so covering vision.

New hope: Cure known as Oraya therapy may help improve the health of unhealthy eyes

Wet AMD is easily the most serious type of AMD because with no treatment sight can deteriorate within days.

Standard treatment involves a shot of anti-vascular endothelial growth factor (anti-VEGF) in to the eye, which prevents further bloodstream ships developing. More...

• Half the outcome of sleep aids 'is because of placebo effect': Findings cast doubt over effectiveness of medicine
• The cancer of the breast patients going through reconstructions using PIG tissue
• Taking aspirin for ten years could double the chance of sight loss

The process must be completed between everybody and three several weeks and just prevents vision from worsening.

The non-invasive Oraya treatments are a 1-time treatment and may enhance the vision of the unhealthy eye.

It calls for a minimal-dose but precisely focused X-ray beam around the macula to hinder the development of bloodstream ships.

The ray also offers the advantage of reducing inflammation and skin damage. Each session takes twenty minutes.

‘Each time the ships leak, it triggers inflammation, which results in skin damage from the macula,’ states Mr Andrew Luff, consultant ophthalmic surgeon in the Optegra Specialist Eye Hospital group, that provides the therapy.

‘This is a huge step forward for individuals struggling with Wet AMD,’ states Luff.

‘Oraya will significantly improve the standard of existence for that patients.’

While not on the NHS, private treatment methods are offered by ?5,145.

• optegra.com